Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group Grows Position in Johnson & Johnson (NYSE:JNJ)

Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group lifted its position in Johnson & Johnson (NYSE:JNJ) by 10.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,771 shares of the company’s stock after acquiring an additional 814 shares during the quarter. Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group’s holdings in Johnson & Johnson were worth $1,282,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Eagle Asset Management Inc. bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $1,446,000. CIBC Private Wealth Group LLC boosted its position in Johnson & Johnson by 0.6% in the fourth quarter. CIBC Private Wealth Group LLC now owns 717,254 shares of the company’s stock worth $112,422,000 after purchasing an additional 3,938 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Johnson & Johnson by 251.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 351,291 shares of the company’s stock valued at $55,061,000 after purchasing an additional 251,420 shares during the last quarter. 1832 Asset Management L.P. raised its stake in shares of Johnson & Johnson by 7.3% during the 4th quarter. 1832 Asset Management L.P. now owns 1,731,472 shares of the company’s stock worth $271,391,000 after purchasing an additional 117,207 shares during the period. Finally, Public Employees Retirement Association of Colorado grew its position in Johnson & Johnson by 589.2% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 358,924 shares of the company’s stock valued at $56,258,000 after buying an additional 306,848 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on JNJ shares. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. TD Securities dropped their price objective on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. TD Cowen decreased their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a report on Friday, September 20th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Stock Down 0.0 %

Shares of NYSE:JNJ opened at $162.02 on Wednesday. The company has a market cap of $389.93 billion, a price-to-earnings ratio of 10.10, a PEG ratio of 2.69 and a beta of 0.53. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The firm has a fifty day moving average price of $162.50 and a two-hundred day moving average price of $154.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm’s revenue was up 4.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.80 earnings per share. Analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.06%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.